Navigation Links
Study shows botanical formula fights prostate cancer
Date:4/10/2012

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells. The study also demonstrated the formula has no toxic side effects, even at high dosages.

"This study is a milestone in the research of this formula, demonstrating its safety and effectiveness in treating human prostate cancer in an animal model," says researcher and formula inventor Dr. Isaac Eliaz. "These positive results offer a significant contribution to prostate cancer research and add to the growing body of published data substantiating the role of natural compounds in the treatment of prostate cancer."

The formula combines botanical extracts, phytonutrients, botanically-enhanced medicinal mushrooms and antioxidants. This is the third study from a major university to demonstrate the formula's ability to suppress tumor growth and metastasis. For more information on the formula, visit www.prostatehealthsolutions.org.

"Multiple studies have demonstrated that this prostate formula is a possible treatment for hormone-refractory prostate cancer," says lead researcher, Dr. Daniel Sliva.

The study found that the orally-administered formula suppressed tumor growth by 27 percent, compared to controls. In addition to significant reduction in tumor volume, the formula inhibited several genes (IGF2, NRNF2 and PLAU/uPA) that encourage cancer proliferation and metastasis. The formula also increased expression of CDKN1A, a gene that fights prostate cancer by inhibiting cancer-promoting cellular mechanisms.

By suppressing genes related to aggressive prostate cancer growth and proliferation, and increasing the expression of cancer-fighting genes, the formula demonstrates multiple anti-cancer mechanisms and genetic targets.

This pre-clinical in vivo study confirms previously published in vitro data, which showed the formula decreases the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.

Prior to this research, the formula was studied at Columbia University and the Cancer Research Laboratory, Methodist Research Institute, at Indiana University Health. These studies also showed the formula inhibits prostate cancer growth and proliferation.


'/>"/>

Contact: Amy Pellegrini
amy@dreliaz.org
707-583-8622
Better Health Publishing
Source:Eurekalert

Related biology news :

1. Approach to diabetes self-management too narrow, study suggests
2. Study finds peoples niceness may reside in their genes
3. Loyola study debunks common myth that urine is sterile
4. UCSB study shows forest insects and diseases arrive in US via imported plants
5. Head and body lice appear to be the same species, genetic study finds
6. Life expectancy may affect when you get married, divorced, have kids: Queens University study
7. Sexual reproduction brings long-term benefits, study shows
8. Researchers use game to change how scientists study disease outbreaks
9. Copper chains: Study reveals Earths deep-seated hold on copper
10. Study shows unified process of evolution in bacteria and sexual eukaryotes
11. Scientists study the catalytic reactions used by plants to split oxygen from water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology: